Revolution Medicines Advances RMC-5127 KRAS Program, Extending Its Oncology Reach

Revolution Medicines, Inc. (RVMD) announced an update on their ongoing clinical study.

Study Overview

Revolution Medicines, Inc. is running a Phase 1/1b trial called “Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors.” The study focuses on patients with hard-to-treat cancers such as lung, colorectal, and pancreatic tumors that carry a KRAS G12V mutation. The main goals are to test safety, dosing, and early signs of tumor control for RMC-5127 alone and in combinations. For investors, this is an early but important effort to open a new slice of the KRAS-driven cancer market, where effective drugs are still limited.

Intervention/Treatment

The trial is testing RMC-5127, an oral cancer drug designed to target tumors with the KRAS G12V mutation. It is given on its own and in two combinations: with daraxonrasib, another oral targeted drug from Revolution Medicines’ pipeline, and with cetuximab, an approved IV cancer antibody. The aim is to see if RMC-5127 can work safely as a stand-alone option and whether pairing it with other drugs improves anti-tumor activity and durability of response.

Study Design

This is an interventional, early-stage study with a treatment focus. Patients are assigned to one of three parallel groups: RMC-5127 alone, RMC-5127 plus daraxonrasib, or RMC-5127 plus cetuximab. The study is non-randomized and open-label, so both doctors and patients know which treatment they receive. The first part escalates doses to find safe levels; the second part expands at those doses to better understand safety and early effectiveness signals that could justify later-stage trials.

Study Timeline

The study was first submitted on January 9, 2026, signaling the formal start of regulatory and site setup activities. It is currently listed as recruiting, meaning patient enrollment is underway. The most recent update to the record was submitted on January 23, 2026, which confirms the protocol and status were reviewed and refreshed. Primary and final completion dates are not yet posted, common for a new Phase 1 study, but investors should assume multi-year timelines before any registrational data emerge.

Market Implications

This update underscores Revolution Medicines’ push to build a broad KRAS-targeted franchise beyond the more crowded KRAS G12C space. If RMC-5127 shows a clean safety profile and early tumor shrinkage, it could support a premium valuation for RVMD’s pipeline and strengthen its position against competitors in precision oncology. The combination arm with daraxonrasib also highlights an in-house combo strategy that may deepen responses and create a more defensible platform. Near term, this news is more about sentiment and story-building than revenue; it may support RVMD shares on optimism around pipeline breadth but will remain high risk until clinical data readouts. For sector investors, this trial adds to the growing focus on mutation-specific therapies in solid tumors and may influence how capital is allocated among small-molecule oncology players.

The study remains ongoing and updated, with further details available on the ClinicalTrials.gov portal.

To learn more about RVMD’s potential, visit the Revolution Medicines, Inc. drug pipeline page.